MX2007003538A - Derivados de ciclosporina 3-eter y 3-tioeter sustituidos para el tratamiento y prevencion de infeccion de hepatitis c. - Google Patents

Derivados de ciclosporina 3-eter y 3-tioeter sustituidos para el tratamiento y prevencion de infeccion de hepatitis c.

Info

Publication number
MX2007003538A
MX2007003538A MX2007003538A MX2007003538A MX2007003538A MX 2007003538 A MX2007003538 A MX 2007003538A MX 2007003538 A MX2007003538 A MX 2007003538A MX 2007003538 A MX2007003538 A MX 2007003538A MX 2007003538 A MX2007003538 A MX 2007003538A
Authority
MX
Mexico
Prior art keywords
cyclosporin
carbon atoms
straight
branched chain
different
Prior art date
Application number
MX2007003538A
Other languages
English (en)
Spanish (es)
Inventor
Hans Georg Fliri
David Renwick Houck
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MX2007003538A publication Critical patent/MX2007003538A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2007003538A 2004-10-01 2005-09-30 Derivados de ciclosporina 3-eter y 3-tioeter sustituidos para el tratamiento y prevencion de infeccion de hepatitis c. MX2007003538A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61515204P 2004-10-01 2004-10-01
US70762605P 2005-08-11 2005-08-11
PCT/US2005/035533 WO2006039668A2 (en) 2004-10-01 2005-09-30 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection

Publications (1)

Publication Number Publication Date
MX2007003538A true MX2007003538A (es) 2008-01-16

Family

ID=36143148

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003538A MX2007003538A (es) 2004-10-01 2005-09-30 Derivados de ciclosporina 3-eter y 3-tioeter sustituidos para el tratamiento y prevencion de infeccion de hepatitis c.

Country Status (19)

Country Link
US (2) US20100167996A1 (enExample)
EP (1) EP1802650B1 (enExample)
JP (2) JP5139065B2 (enExample)
KR (1) KR101309409B1 (enExample)
CN (1) CN101773661B (enExample)
AT (1) ATE530561T1 (enExample)
AU (1) AU2005292162B2 (enExample)
BR (1) BRPI0516737A (enExample)
CA (1) CA2583494C (enExample)
DK (1) DK1802650T3 (enExample)
ES (1) ES2373450T3 (enExample)
IL (1) IL182315A (enExample)
MX (1) MX2007003538A (enExample)
NZ (1) NZ554514A (enExample)
PL (1) PL1802650T3 (enExample)
PT (1) PT1802650E (enExample)
RU (1) RU2399628C2 (enExample)
SI (1) SI1802650T1 (enExample)
WO (1) WO2006039668A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006054801A1 (en) 2004-11-22 2006-05-26 Astellas Pharma Inc. New cyclic peptide compound
JP5322647B2 (ja) * 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US7754685B2 (en) * 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
US7872097B2 (en) 2005-10-26 2011-01-18 Astellas Pharma Inc. Cyclic peptide compounds
US7825152B2 (en) 2006-04-11 2010-11-02 Novartis Ag Organic compounds and their uses
US8188052B2 (en) * 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
SG175621A1 (en) * 2006-10-12 2011-11-28 Novartis Ag Use of modified cyclosporins
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
US8603975B2 (en) 2007-05-02 2013-12-10 Astellas Pharma Inc. Cyclic peptide compounds
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
CA2724523A1 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
JP5726733B2 (ja) 2008-07-30 2015-06-03 シクロフィリン ファーマシューティカルズ コープ． 非免疫抑制性シクロスポリン類似体分子
WO2010076329A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
MX2011007195A (es) * 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
CA2751210C (en) * 2009-01-30 2015-04-21 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
CA2782898A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
MX2012007076A (es) * 2009-12-18 2012-07-20 Boehringer Ingelheim Int Terapia combinada de hcv.
CN102834409A (zh) 2009-12-30 2012-12-19 西尼克斯公司 环孢菌素类似物
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
CN103153329A (zh) 2010-07-16 2013-06-12 美国科技环球有限公司 新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
CN103153330B (zh) 2010-08-12 2017-08-18 美国科技环球有限公司 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用
CA2811799A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
ES2625502T3 (es) * 2010-12-03 2017-07-19 S&T Global Inc Nuevos derivados de ciclosporina para el tratamiento y prevención de una infección vírica
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
TR201900128T4 (tr) 2010-12-15 2019-02-21 Contravir Pharmaceuticals Inc Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller.
RU2448690C1 (ru) * 2011-03-15 2012-04-27 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма пролонгированного действия нестероидного противовоспалительного средства кетопрофен, способ получения
CN103987399A (zh) * 2011-08-19 2014-08-13 美国科技环球有限公司 用于治疗和预防病毒感染的新型环孢菌素衍生物
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
EP3038626A4 (en) * 2013-08-26 2017-04-19 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
WO2016160362A1 (en) 2015-03-31 2016-10-06 Allergan, Inc. Cyclosporins modified on the mebmt sidechain by heterocyclic rings
CN108025039B (zh) * 2015-06-30 2022-07-29 西普拉里斯有限公司 新颖的大环化合物
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
JP2022551161A (ja) 2019-10-12 2022-12-07 ファーサイト メディカル テクノロジー （シャンハイ） カンパニー リミテッド ネフロトキシン誘発性腎障害の処置及び予防
EP4126905A4 (en) * 2020-03-26 2024-05-29 Farsight Medical Technology (Shanghai) Co., Ltd. CYCLOPHILIN INHIBITORS AND THEIR USES
WO2021209003A1 (en) * 2020-04-15 2021-10-21 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) * 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) * 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
DE69124459T3 (de) * 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
WO1994022896A1 (fr) * 1993-03-31 1994-10-13 Tokyo Tanabe Company Limited Ameliorant de la cholestase
WO1995003056A1 (en) * 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
AU2577295A (en) * 1994-06-01 1995-12-21 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
HUP9900405A3 (en) * 1995-07-17 2001-04-28 Scynexis Inc Durham Cyclosporin derivatives with anti-hiv effect
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
CN1205220C (zh) * 1998-06-12 2005-06-08 斯－凯穆公司 新颖的环孢菌素
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
BR9911724A (pt) * 1998-07-01 2001-03-20 Debiopharm Sa Ciclosporina que tem um perfil de atividade melhorado
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6521595B1 (en) * 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
MY139078A (en) * 2000-07-21 2009-08-28 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
KR20040039622A (ko) * 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP5322647B2 (ja) * 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US7754685B2 (en) * 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
US8188052B2 (en) * 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
CA2724523A1 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
WO2010076329A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
CN102271688A (zh) * 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv的环孢菌素衍生物和核苷的组合
MX2011007195A (es) * 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
CA2782898A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides

Also Published As

Publication number Publication date
WO2006039668A2 (en) 2006-04-13
US20120264679A1 (en) 2012-10-18
HK1108703A1 (en) 2008-05-16
WO2006039668B1 (en) 2007-05-31
CN101773661B (zh) 2013-09-25
BRPI0516737A (pt) 2008-04-29
ATE530561T1 (de) 2011-11-15
PL1802650T3 (pl) 2012-04-30
ES2373450T3 (es) 2012-02-03
US20100167996A1 (en) 2010-07-01
JP2008514732A (ja) 2008-05-08
EP1802650A2 (en) 2007-07-04
PT1802650E (pt) 2011-12-30
JP5139065B2 (ja) 2013-02-06
AU2005292162A1 (en) 2006-04-13
KR20070073841A (ko) 2007-07-10
IL182315A0 (en) 2007-07-24
AU2005292162B2 (en) 2011-11-10
NZ554514A (en) 2010-10-29
KR101309409B1 (ko) 2013-09-23
DK1802650T3 (da) 2012-02-06
CN101773661A (zh) 2010-07-14
RU2399628C2 (ru) 2010-09-20
RU2007116119A (ru) 2008-11-10
EP1802650A4 (en) 2008-08-20
SI1802650T1 (sl) 2012-03-30
CA2583494C (en) 2014-01-21
WO2006039668A3 (en) 2007-04-19
CA2583494A1 (en) 2006-04-13
JP2012167113A (ja) 2012-09-06
EP1802650B1 (en) 2011-10-26
IL182315A (en) 2013-08-29

Similar Documents

Publication Publication Date Title
EP1802650B1 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
US7718767B2 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP5820722B2 (ja) シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
RU2440822C2 (ru) Способы и фармацевтические композиции для лечения и профилактики инфекции гепатита с
JP2013513595A (ja) 新規環状ペプチド
CN101068829B (zh) 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
US20120010131A1 (en) Novel cyclosporin analogues
US10738084B2 (en) Macrocycles
HK1108703B (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection

Legal Events

Date Code Title Description
FG Grant or registration